Clinical Trial

Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary purpose of this study is to compare the quality of life (QOL) reported by prostate cancer patients 2 years after treatment with ultra-hypofractionated post-prostatectomy radiation therapy (also known as stereotactic body radiation therapy \[SBRT\]) versus the self-reported QOL of those treated with moderately hypo-fractionated post-prostatectomy radiation (a current standard of care option).
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2021-08-31; most recent amendment 2026-01-15.
Status change: Not Yet Recruiting → Recruiting 2021-12-16
Trial Details
NCT Number NCT05038332
Lead Sponsor University of Michigan Rogel Cancer Center
Conditions Prostate Cancer
Enrollment 136 participants
Start Date 2021-11-12
Primary Completion 2026-11 (estimated)
Study Completion 2029-11 (estimated)
Updated on ClinicalTrials.gov 2026-01-16